Conference Call with Ambuja Cements Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Heavy Electrical Equipment company Hitachi Energy India announced Q2FY26 results Orders totaled Rs 2,217.1 crore, up 13.6% YoY. Revenue: Rs 1,915.2 crore compared to Rs 1,553.8 crore during Q2FY25, change 23.3%. EBITDA: Rs 291.6 crore compared to Rs 126.3 crore during Q2FY25, change 130.5%. EBITDA Margin: 15.2% for Q2FY26. PBT: Rs 352.9 crore compared to Rs 70.6 crore during Q2FY25, change 399.8%. PAT: Rs 264.4 crore compared to Rs 52.3 crore during Q2FY25, change 405.6%. N Venu, Managing Director & CEO, Hitachi Energy India, said: "The country has successfully built-up its non-fossil fuel energy installed base, to 50 percent of its electricity generation capacity. This notable milestone brings with it the challenges of seamlessly integrating intermittent, distributed energy into the national grid. It is essential that we enhance the resilience, reliability, and intelligence of the whole energy ecosystem to e?ectively deploy the expanding capacity. This shifts the focus to advanced grid technologies, digitalization, and integrated solutions, which is reflected in our operations and financial performance." Result PDF
Pharmaceuticals company Gland Pharma announced Q2FY26 results Consolidated Financial Highlights: Quarterly revenue increased by 6% year-on-year; Half yearly revenues increased by 7% Quarterly R&D; investments increase to Rs 614 million against Rs 460 million in previous quarter Quarterly EBITDA increased by 6% year-on-year; Half yearly EBITDA increased by 21% Quarterly EBITDA margin stood at 21%; Half yearly EBITDA margin was at 23% Quarterly adj. EBITDA increased by 13% year-on-year; Half yearly adj. EBITDA increased by 26% Quarterly adj. EBITDA margin increased by 150 bps year-on-year; Half yearly adj. EBITDA margin increased by 370 bps Quarterly PAT increased by 12% year-on-year; Half yearly PAT increased by 30% Quarterly PAT margin increased by 70 bps year-on-year; Half yearly PAT margin increased by ~240 bps Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Gland Pharma delivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY. We expect stronger momentum in the second half, driven by new launches and Cenexi’s recovery. Our investments in global CDMO expansion, capacity enhancement in high end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders.” Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “For the quarter, Gland Pharma’s core business maintained its profitable growth trajectory with strong margin expansion. Encouragingly for consolidated business, we saw year-over-year improvement during the Q2FY26 with USA growing by 10% and Europe by 16%, supported by a 21% top-line increase in Cenexi. With the current momentum, we anticipate a robust growth in the upcoming quarters.” Result PDF